Cross-protective responses to human papillomavirus infection

Future Virology

Volumn 5, Issue 2, 2010, Pages 163-174

  Christensen, N D ^a   Bounds, C E ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cervical cancer; Cross protection; Human papillomavirus; L1; Major capsid protein; Neutralization; Oncogenic types; Pseudovirus; Vaccine; Virus like particle

Indexed keywords

COAT PROTEIN; NEUTRALIZING ANTIBODY; WART VIRUS VACCINE;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; CROSS PROTECTION; DEVELOPING COUNTRY; DRUG RESEARCH; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; MORTALITY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SEQUENCE ALIGNMENT; T LYMPHOCYTE; UTERINE CERVIX CANCER; VIRION; VIRUS CARCINOGENESIS; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WART VIRUS;

EID: 77649291847     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.1     Document Type: Review

References (111)

1. zur Hausen H: Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384, 260-265 (2009).
2. zur Hausen H: Perspectives of contemporary papillomavirus research. Vaccine 24(Suppl. 3), S3iii-S3iiv (2006).
3. Munoz N, Bosch FX, De Sanjose S et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Eng. J. Med. 348, 518-527 (2003).
4. Capone RB, Pai SI, Koch WM et al.: Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin. Cancer Res. 6, 4171-4175 (2000).
5. Gillison ML, Koch WM, Capone RB et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl Cancer Inst. 92, 709-720 (2000).
6. Koutsky LA, Ault KA, Wheeler CM et al.: A controlled trial of a human papillomavirus type 16 vaccine. N. Eng. J. Med. 347, 1645-1651 (2002).
7. Garland SM, Hernandez-Avila M, Wheeler CM et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356, 1928-1943 (2007).
8. Christensen ND, Kreider JW: Antibody-mediated neutralization in vivo of infectious papillomaviruses. J. Virol. 64, 3151-3156 (1990).
9. Kirnbauer R, Chandrachud LM, O'Neil BW et al.: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219, 37-44 (1996).
10. Breitburd F, Kirnbauer R, Hubbert NL et al.: Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69, 3959-3963 (1995).
11. Mejia AF, Culp TD, Cladel NM et al.: Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J. Virol. 80, 12393-12397 (2006).
12. Ault KA: Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol. Oncol. 107, S31-S33 (2007).
13. Brown DR, Kjaer SK, Sigurdsson K et al.: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199, 926-935 (2009).
14. Olsson SE, Kjaer SK, Sigurdsson K et al.: Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum. Vaccin. 5(10) (2009) (Epub ahead of print).
15. Ho GY, Studentsov Y, Hall CB et al.: Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J. Infect. Dis. 186, 737-742 (2002).
16. Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT: Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270, 254-257 (2000).
17. Pastrana DV, Gambhira R, Buck CB et al.: Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337, 365-372 (2005).
18. Gambhira R, Jagu S, Karanam B et al.: Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J. Virol. 81, 11585-11592 (2007).
19. Belnap DM, Olson NH, Cladel NM et al.: Conserved features in papillomavirus and polyomavirus capsids. J. Mol. Biol. 259, 249-263 (1996).
20. McCoy EG, Boyle WF, Fogarty WA: Electron microscopic identification of virus-like particles in laryngeal papilloma. Ann. Otol. Rhinol. Laryngol. 80, 693-698 (1971).
21. Syrjanen K, Vayrynen M, Hippelainen M, Castren O, Saarikoski S, Mantyjarvi R: Electron microscopic assessment of cervical punch biopsies in women followed-up for human papillomavirus (HPV) lesions. Arch. Geschwulstforsch. 55, 131-138 (1985).
22. Klug A, Finch JT: Structure of viruses of the papilloma-polyoma type. I. Human wart virus. J. Mol. Biol. 11, 403-423 (1965).
23. Trus BL, Roden RB, Greenstone HL, Vrhel M, Schiller JT, Booy FP: Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nat. Struct. Biol. 4, 413-420 (1997).
24. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC: Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell 5, 557-567 (2000).
25. Bishop B, Dasgupta J, Klein M et al.: Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J. Biol. Chem. 282, 31803-31811 (2007).
26. Modis Y, Trus BL, Harrison SC: Atomic model of the papillomavirus capsid. EMBO J. 21, 4754-4762 (2002).
27. Meyers C, Frattini MG, Hudson JB, Laimins LA: Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257, 971-973 (1992).
28. Buck CB, Pastrana DV, Lowy DR, Schiller JT: Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 119, 445-462 (2005).
29. Pyeon D, Lambert PF, Ahlquist P: Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc. Natl. Acad. Sci. USA 102, 9311-9316 (2005).
30. Li ML, Cripe TP, Estes PA, Lyon MK, Rose RC, Garcea RL: Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J. Virol. 71, 2988-2995 (1997).
31. Hoffmann KJ, Cook JC, Joyce JG et al.: Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology 209(2), 506-518 (1995).
32. Rose RC, Bonnez W, Reichman RC, Garcea RL: Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus like particles. J. Virol. 67, 1936-1944 (1993).
33. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS: Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 224, 477-486 (1996).
34. Selinka H-C, Giroglou T, Christensen ND, Sapp M: Further evidence that papillomavirus capsids exist in two distinct conformations. J. Virol. 77(24), 12961-12967 (2003).
35. Culp TD, Spatz CM, Reed CA, Christensen ND: Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 361, 435-446 (2007).
36. Conway MJ, Alam S, Christensen ND, Meyers C: Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteines. Virology 393, 295-303 (2009).
37. Christensen ND, Kreider JW, Kan NC, DiAngelo SL: The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 181, 572-579 (1991).
38. Gaukroger JM, Chandrachud LM, O'Neil BW, Grindlay GJ, Knowles G, Campo MS: Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus neutralizing antibodies. J. Gen. Virol. 77, 1577-1584 (1996).
39. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T: Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J. Virol. 73, 6188-6190 (1999).
40. Jin XW, Cowsert LM, Pilacinski WP, Jenson AB: Identification of L2 open reading frame gene products of bovine papillomavirus type 1 using monoclonal antibodies. J. Gen. Virol. 70, 1133-1140 (1989).
41. Christensen ND, Kreider JW, Cladel NM, Patrick SD, Welsh PA: Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J. Virol. 64, 5678-5681 (1990).
42. Cowsert LM, Pilacinski WP, Jenson AB: Identification of the bovine papillomavirus L1 gene product using monoclonal antibodies. Virology 165, 613-615 (1988).
43. Rizk RZ, Christensen ND, Michael KM et al.: Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J. Gen. Virol. 89, 117-129 (2008).
44. Ludmerer SW, Benincasa D, Mark GE 3rd: Two amino acid residues confer type-specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J. Virol. 70, 4791-4794 (1996).
45. Christensen ND, Cladel NM, Reed CA et al.: Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291, 324-334 (2002).
46. Carter JJ, Wipf GC, Benki SF, Christensen ND, Galloway DA: Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J. Virol. 77, 11625-11632 (2003).
47. Carter JJ, Wipf GC, Madeleine MM, Schwartz SM, Koutsky LA, Galloway DA: Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J. Virol. 80, 4664-4672 (2006).
48. Wang Z, Christensen N, Schiller JT, Dillner J: A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J. Gen. Virol. 78(Pt 9), 2209-2215 (1997).
49. Opalka D, Lachman CE, MacMullen SA et al.: Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin. Diagn. Lab Immunol. 10, 108-115 (2003).
50. Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P: Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J. Virol. 76, 6480-6486 (2002).
51. Govan VA, Christensen ND, Berkower C, Jacobs WR Jr, Williamson AL: Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine 24, 2087-2093 (2006).
52. Gambhira R, Karanam B, Jagu S et al.: A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J. Virol. 81, 13927-13931 (2007).
53. Embers ME, Budgeon LR, Pickel M, Christensen ND: Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J. Virol. 76, 9798-9805 (2002).
54. Slupetzky K, Gambhira R, Culp TD et al.: A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25, 2001-2010 (2007).
55. Dessy FJ, Giannini SL, Bougelet CA et al.: Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum. Vaccin. 4, 425-434 (2008).
56. Roden RBS, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT: Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J. Virol. 70, 3298-3301 (1996).
57. Giannini SL, Hanon E, Moris P et al.: Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared with aluminium salt only. Vaccine 24, 5937-5949 (2006).
58. Harper DM, Franco EL, Wheeler CM et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18, follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006).
59. Villa LL, Costa RL, Petta CA et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. 6, 271-278 (2005).
60. Kjaer SK, Sigurdsson K, Iversen OE et al.: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. 2, 868-878 (2009).
61. Viscidi RP, Schiffman M, Hildesheim A et al.: Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol. Biomarkers Prev. 13, 324-327 (2004).
62. Viscidi RP, Snyder B, Cu-Uvin S et al.: Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol. Biomarkers Prev. 14, 283-288 (2005).
63. Carter JJ, Koutsky LA, Wipf GC et al.: The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J. Infect. Dis. 174, 927-936 (1996).
64. Zhang LF, Zhou J, Chen S et al.: HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18, 1051-1058 (2000).
65. Christensen ND, Han R, Cladel NM, Pickel MD: Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences. Antimicrob. Agents Chemother. 45, 1201-1209 (2001).
66. Giroglou T, Sapp M, Lane C et al.: Immunological analyses of human papillomavirus capsids. Vaccine 19, 1783-1793 (2001).
67. Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E: Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26, 686-696 (2008).
68. Bonanni P, Boccalini S, Bechini A: Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 27(Suppl. 1), A46-A53 (2009).
69. Paavonen J, Naud P, Salmeron J et al.: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374, 301-314 (2009).
70. Romanowski B, Colares de Borba P, Naud PS et al.: Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years. Lancet 374, 1975-1985 (2009).
71. Jansen KU, Rosolowsky M, Schultz LD et al.: Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13, 1509-1512 (1995).
72. Suzich JA, Ghim SJ, Palmer-Hill FJ et al.: Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA 92, 11553-11557 (1995).
73. Smith LH, Foster C, Hitchcock ME et al.: Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro. J. Invest. Dermatol. 105, 438-444 (1995).
74. Kreider JW, Howett MK, Lill NL et al.: In vivo transformation of human skin with human papillomavirus type 11 from condylomata acuminata. J. Virol. 59, 369-376 (1986).
75. Christensen ND, Koltun WA, Cladel NM et al.: Coinfection of human foreskin fragments with multiple human papillomavirus types (HPV-11, -40, -LVX82/MM7) produces regionally separate HPV infections within the same athymic mouse xenograft. J. Virol. 71, 7337-7344 (1997).
76. Bonnez W, DaRin C, Borkhuis C, De Mesy Jensen KL, Reichman RC, Rose RC: Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse. J. Virol. 72, 5256-5261 (1998).
77. Meyers C, Mayer TJ, Ozbun MA: Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J. Virol. 71, 7381 (1997).
78. McLaughlin-Drubin MA, Suzich JA, Mullikin B, White WI, Meyers C: Human papillomavirus type 45 propagation, infection, and neutralization. Virology 312(1), 1-7 (2003).
79. Pastrana DV, Buck CB, Pang YY et al.: Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321, 205-216 (2004).
80. Müller M, Gissmann L, Cristiano RJ et al.: Papillomavirus capsid binding and uptake by cells from different tissues and species. J. Virol. 69, 948-954 (1995).
81. Zhou J, Gissmann L, Zentgraf H, Müller H, Picken M, Müller M: Early phase in the infection of cultured cells with papillomavirus virions. Virology 214, 167-176 (1995).
82. Unckell F, Streeck RE, Sapp M: Generation and neutralization of pseudovirions of human papillomavirus type 33. J. Virol. 71, 2934-2939 (1997).
83. Sapp M, Day PM: Structure, attachment and entry of polyoma- and papillomaviruses. Virology 384, 400-409 (2009).
84. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NAJ: Identification of the a(6) integrin as a candidate receptor for papillomaviruses. J. Virol. 71, 2449-2456 (1997).
85. Culp TD, Budgeon LR, Christensen ND: Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology 347, 147-159 (2006).
86. Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT: Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 81, 8784-8792 (2007).
87. Christensen ND, Cladel NM, Reed CA: Postattachment neutralization of papillomaviruses by monoclonal and polyclonal antibodies. Virology 207, 136-142 (1995).
88. Selinka HC, Florin L, Patel HD et al.: Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J. Virol. 81, 10970-10980 (2007).
89. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT: Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. J. Virol. 82, 4638-4646 (2008).
90. Palmer KE, Benko A, Doucette SA et al.: Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine 24, 5516-5525 (2006).
91. Parker DC: T cell-dependent B cell activation. Annu. Rev. Immunol. 11, 331-360 (1993).
92. Yao Q, Zhang R, Guo L, Li M, Chen C: Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine. J. Immunol. 173, 1951-1958 (2004).
93. Zinkernagel RM, Bachmann MF, Kundig TM, Oehen S, Pirchet H, Hengartner H: On immunological memory. Annu. Rev. Immunol. 14, 333-367 (1996).
94. Hong K, Greer CE, Ketter N, Van Nest G, Paliard X: Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts. J. Virol. 71, 6427-6432 (1997).
95. Alloub MI, Barr BBB, McLaren KM, Smith IW, Bunney MH, Smart GE: Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. Br. Med. J. 298, 153-156 (1989).
96. Gassenmaier A, Fuchs P, Schell H, Pfister H: Papillomavirus DNA in warts of immunosuppressed renal allograft recipients. Arch. Dermatol. Res. 278, 219-223 (1986).
97. Henry MJ, Stanley MW, Cruikshank S, Carson L: Association of human immunodeficiency virus induced immunosuppression with human papillomavirus infection and cervical intraepithelial neoplasia. Am. J. Obstet. Gynecol. 160, 352-353 (1989).
98. Johnson JC, Burnett AF, Willet GD, Young MA, Doniger J: High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women. Obstet. Gynecol. 79, 321-327 (1992).
99. Petry KU, Scheffel D, Bode U et al.: Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int. J. Cancer 57, 836-840 (1994).
100. + lymphocytes. Virology 283, 31-39 (2001).
101. + cells and persistence of viral DNA after regression. J. Virol. 71, 5540-5548 (1997).
102. Stanley MA: Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Expert Rev. Vaccines 2, 381-389 (2003).
103. Fausch SC, Da Silva DM, Eiben GL, Le Poole IC, Kast WM: HPV protein/peptide vaccines: from animal models to clinical trials. Front. Biosci. 8, S81-S91 (2003).
104. + T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types. J. Virol. 76, 7418-7429 (2002).
105. + T cells fail to control tumor growth despite interferon-γ production in patients with cervical cancer. J. Immunother. 30, 523-532 (2007).
106. Pinto LA, Edwards J, Castle PE et al.: Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. 188, 327-338 (2003).
107. De Bruijn ML, Greenstone HL, Vermeulen H et al.: L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250, 371-376 (1998).
108. Hu J, Cladel NM, Budgeon LR, Reed CA, Pickel MD, Christensen ND: Protective cell-mediated immunity by DNA vaccination against papillomavirus L1 capsid protein in the cottontail rabbit papillomavirus model. Viral Immunol. 19, 492-507 (2006).
109. Pinto LA, Viscidi R, Harro CD et al.: Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 353, 451-462 (2006).
110. McClements WL, Wang XM, Ling JC et al.: A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology 289, 262-268 (2001).
111. Ludmerer SW, McClements WL, Wang XM, Ling JC, Jansen KU, Christensen ND: HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Virology 266, 237-245 (2000).